Biotron
Biotron Limited is an Australian biotechnology company developing a new class of antiviral therapies. Their lead compound, BIT225, is in Phase 2 development for HIV-1 and Hepatitis C, with promising activity against SARS-CoV-2. The company focuses on targeting viroporin proteins, which are key to viral pathogenicity, and has a robust pipeline of compounds active against various viral diseases.
Industries
Nr. of Employees
medium (51-250)
Biotron
Level 2, 66 Hunter Street, Sydney NSW 2000, Australia
Products
Lead clinical small-molecule viroporin inhibitor (lead compound)
A lead small-molecule viroporin inhibitor in Phase 2 clinical development for treatment of HIV-1 and hepatitis C virus; reported to inhibit viral replication in macrophage reservoir cells and demonstrated early-stage activity against other viruses including SARS‑CoV‑2.
Lead clinical small-molecule viroporin inhibitor (lead compound)
A lead small-molecule viroporin inhibitor in Phase 2 clinical development for treatment of HIV-1 and hepatitis C virus; reported to inhibit viral replication in macrophage reservoir cells and demonstrated early-stage activity against other viruses including SARS‑CoV‑2.
Services
End-to-end internal programs to discover, preclinically evaluate and clinically develop small-molecule antivirals targeting viroporins.
End-to-end internal programs to discover, preclinically evaluate and clinically develop small-molecule antivirals targeting viroporins.
Expertise Areas
- Viroporin-targeted antiviral discovery
- Small-molecule antiviral development
- Preclinical antiviral testing (in vitro and in vivo)
- Phase 2 clinical program execution
Key Technologies
- Viroporin-targeted small molecules
- Bacterial cell-based screening platform
- High-throughput cell-based antiviral assays
- Curated small-molecule compound library
News & Updates
Update on the company's hepatitis B virus program as of June 2025.
Announcement regarding the change of the company's share registry address in June 2025.
Quarterly activities report for March 2025.
A publication detailing the validation of a new drug mechanism for HIV treatment.
An article discussing the company's involvement in the hepatitis C market.
Cosmos Magazine article about the challenges of developing new biotech ideas.
Update on the company's hepatitis B virus program as of June 2025.
Announcement regarding the change of the company's share registry address in June 2025.
Quarterly activities report for March 2025.
A publication detailing the validation of a new drug mechanism for HIV treatment.
An article discussing the company's involvement in the hepatitis C market.
Cosmos Magazine article about the challenges of developing new biotech ideas.